5,400
-1.46%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ildong Holdings Co
Its shares trade on KRX under the ticker 000230.KS. It has been listed since 28 June 1975. In the fiscal year to 31 December 2025, it reported revenue of ₩590.89bn and net income of ₩10.93bn. At that date it held total assets of ₩802.86bn and shareholders' equity of ₩168.76bn.
Ildong Holdings Co., Ltd. engages in the management of subsidiaries. The company is headquartered in Seoul, Seoul. The Company’s products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. The company also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Jun 1975
- Employees
- 84
- Website
- ildongholdings.co.kr ↗
Leadership
Pay as last reported
- Mr. Won Yeong YoonChairman, since 2021₩663.4m
- Mr. Dae Chang ParkChief Executive Officer, Vice Chairman₩600.9m
- Mr. Gyu Seong KangManaging Director, since 2021
- Mr. Gyu Hwan ChoiManaging Director
- Mr. Nam Yik KimInternal Auditor
- Mr. Jeong Nam ParkAssistant Managing Director
- Ms. Ah Jeong ShinAssistant Managing Director
- Mr. Ju Hyeong SungInternal Auditor
- Mr. Wung Seop YoonDirector
- Mr. Hui Seok KimNon-Executive Independent Director
- Mr. Jun Hong ParkNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ildong Holdings manages subsidiaries with 84 employees in Seoul, South Korea.
- Ildong Holdings offers general drugs, specialty drugs, and raw materials like probiotics and synthesises.
- Ildong Holdings provides diverse services through subsidiaries including advertising, medical equipment, and software development.
Weaknesses
- Ildong Holdings has only 84 employees, which may limit operational capacity.
- Ildong Holdings' product range includes only general and specialty drugs without new innovations.
- Ildong Holdings' subsidiaries focus on advertising, medical equipment, and software without clear market dominance.
Opportunities
- Ildong Holdings can expand its pharmaceutical products to include new drug categories.
- Ildong Holdings can leverage its Seoul headquarters for international market access.
- Ildong Holdings can grow its raw materials business with probiotics and synthesises.
Threats
- Ildong Holdings faces competition from other pharmaceutical companies in South Korea.
- Ildong Holdings must comply with South Korean pharmaceutical regulations.
- Ildong Holdings' small employee count may hinder growth in a competitive market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.